Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,205
datasets available to search
ShareScore release 0.9.0
Dataset results
1,205 results for “vaccine responses”
Influenza Vaccines Differentially Regulate the Interferon Response in Human Dendritic Cell Subsets [HumanWG-6 v3.0 Beadchip Experiments]
GEO Series GSE81690. Homo sapiens. 108 samples. Type: Expression profiling by array.
Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers
GEO Series GSE39506. Homo sapiens. 161 samples. Type: Expression profiling by array.
Immune-aging is linked to clinical malignancy and vaccine responses in myeloma
GEO Series GSE288020. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing; Other.
Transcriptomic analysis reveals differential response in the teleost spleens and head kidneys towards vaccination and pathogen challenge
GEO Series GSE51839. Lates calcarifer. 57 samples. Type: Expression profiling by array.
Longitudinal Multiomic Profiling and Corticosteroid Modulation of the Immediate Innate Immune Response to an Adenovirus-vector Vaccine
GEO Series GSE269423. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response Against Influenza Virus
GEO Series GSE135761. Mus musculus. 1475 samples. Type: Expression profiling by high throughput sequencing.
Comprehensive comparison of adaptive immune response by inactivated SARS-CoV-2 vaccine between young and old
GEO Series GSE191089. Homo sapiens. 9 samples. Type: Other; Expression profiling by high throughput sequencing.
Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"
<p>This record contains data related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"</p> <p>The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (p &amp;lt; 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of &amp;gt;1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, p &amp;lt; 0.0001). Moreover, in the seroconverted patients, a daily dose of &amp;gt;1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of &amp;gt;1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.</p>
Early dendritic cell molecular signature modelling predicts late vaccine-induced adaptive T-cell responses (Codelink)
GEO Series GSE66930. Mus musculus. 113 samples. Type: Expression profiling by array.
Early dendritic cell molecular signature modelling predicts late vaccine-induced adaptive T-cell responses (Illumina)
GEO Series GSE66797. Mus musculus. 117 samples. Type: Expression profiling by array.
Anti-glycan humoral responses after vaccination with PROSTVAC-VF
GEO Series GSE50410. Medicago sativa; Gallus gallus; Megathura crenulata; Rhodotorula; Bos taurus; Ovis aries; Mus musculus; Frangula alnus; Senegalia senegal; Dermestes lardarius; Quercus alba; Bothrops moojeni; Pachymenia carnosa; Gossypium hirsutum; Pandalus borealis; Homo sapiens. 564 samples. Type: Protein profiling by protein array.
Human DNA methylation profiles for the HBV vaccine responses study
GEO Series GSE48300. Homo sapiens. 25 samples. Type: Methylation profiling by array.
FLUAV RAM-IGIP: A modified live influenza virus vaccine that enhances humoral and mucosal responses against influenza. Vaccine Encoding the IgA-Inducing Protein
GEO Series GSE252919. Influenza A virus; Mus musculus. 112 samples. Type: Protein profiling by protein array.
Influenza Vaccines Differentially Regulate the Interferon Response in Human Dendritic Cell Subsets
GEO Series GSE81692. Homo sapiens. 117 samples. Type: Expression profiling by array.
T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination
GEO Series GSE58970. Homo sapiens. 147 samples. Type: Expression profiling by array.
Early antiviral responses in monocytes and dendritic cells are associated with persistent humoral immunity to pertussis following Tdap-IPV vaccination
GEO Series GSE195627. Homo sapiens. 80 samples. Type: Expression profiling by high throughput sequencing.
Immune and transcriptomic response to seasonal influenza vaccination (TIV) in mice
GEO Series GSE68771. Mus musculus. 66 samples. Type: Expression profiling by high throughput sequencing.
Yellow fever vaccine propagation in primary human hepatocytes triggers antiviral and cytolytic responses
GEO Series GSE306280. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing.
Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention.
<p>Dataset from Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, Dubini C, Prandoni I, Capitanio G, Renna LV, Boveri S, Rigolini R, Carrara M, Spuria G, Cuppone T, D'acquisto A, Carpinelli L, Sacchi M, Morricone L, Secchi F, Costa E, Menicanti L, Nisoli E, Carruba M, Ambrogi F, Corsi Romanelli MM. Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). 2021 Nov 30. doi: 10.1002/oby.23353. Epub ahead of print. PMID: 34850576.</p> <p>Abstract</p> <p><strong>Objective: </strong>The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2 specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals with AO to those without, discerning between individuals with or without prior infection.</p> <p><strong>Methods: </strong>IgG neutralizing antibodies against the Trimeric-complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, at one and three months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO.</p> <p><strong>Results: </strong>Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p<0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p<0.001).</p> <p><strong>Conclusions: </strong>The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions including obesity and particularly to those with more prevalent abdominal obesity phenotype.</p>
Link to dataset related to article "mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients"
<p>This record contains raw data related to article “mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients"</p> <p>SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is progressively us allowing to overcome the pandemic. Recent evidence has shown that response to vaccination in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-γ T-cell response in 328 subjects, including 131 immunocompromised individuals (cancer, rheumatologic, and hemodialysis patients), 160 health-care workers (HCW) and 37 subjects older than 75 yr, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according to the type of treatment. We found that immunocompromised patients, depending on the type of treatment, poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-CoV-2-specific immune response than those who are vaccinated without prior infection.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.